Quoin Pharmaceuticals Ltd ((QNRX)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Quoin Pharmaceuticals Ltd is conducting a clinical study titled ‘A Multicenter, Open Label Study of QRX003 Lotion in Subjects With Netherton Syndrome.’ The study aims to evaluate the safety, tolerability, and efficacy of QRX003 lotion when added to the standard care regimen for individuals with Netherton Syndrome, a rare genetic skin disorder. This research is significant as it could offer a new treatment option for patients suffering from this condition.
The intervention being tested is QRX003, a 4% topical lotion containing a serine protease inhibitor. It is designed to be applied either once daily in the morning or twice daily, aiming to improve skin condition and patient outcomes.
This interventional study follows a non-randomized, single-group, open-label design, focusing on treatment as its primary purpose. The open-label nature means both researchers and participants know which treatment is being administered.
The study began on March 16, 2023, with its primary completion and estimated overall completion set for March 28, 2025. These dates are crucial as they mark the timeline for data collection and analysis, impacting future treatment availability.
The ongoing study could influence Quoin Pharmaceuticals’ stock performance positively if results prove favorable, potentially enhancing investor confidence. This update places Quoin in a competitive position within the pharmaceutical industry, particularly in the niche market of rare skin disorders.
The study is currently recruiting, with further details available on the ClinicalTrials portal.